Trevi Therapeutics, Inc.

NASDAQ•TRVI

CEO: Ms. Jennifer L. Good

セクター: Healthcare

業種: Biotechnology

上場日: 2019-05-07

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

連絡先情報

195 Church Street, 16th Floor, New Haven, CT, 06510, United States

203-304-2499

www.trevitherapeutics.com

時価総額

$1.66B

PER (TTM)

-40.9

19.7

配当利回り

52週高値

$14.39

52週安値

$4.24

52週レンジ

86%

順位62Top 92.6%

1.9

F-Score

改良版 Piotroski 分析

9年ファンダメンタル

弱い • 1.9 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2017-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.08-38.46%

直近4四半期の推移

フリーCF

-$10.89M+13.98%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Strong Financing Cash Inflow Net cash from financing activities totaled $120.7M, driven by June 2025 offering, boosting cash reserves to $56.9M.

Positive Phase 2b Trial Results CORAL trial met primary endpoint; 108 mg BID dose showed 60.2% reduction in 24-hour cough frequency versus placebo.

Net Loss Narrows Significantly Nine months net loss reduced to $34.4M from $36.5M, reflecting lower R&D spending compared to the prior year period.

Extended Cash Runway Forecast Total cash and marketable securities reached $193.9M, expected to fund operations and capital needs into fiscal year 2028.

リスク要因

Need Substantial Future Funding Substantial expenditures expected for Phase 3 trials; failure to raise capital timely could delay or force abandonment of development.

Increased Operating Cash Burn Operating activities used $34.5M cash in nine months, up from $28.7M last year, increasing cash burn rate significantly.

Sole Product Candidate Dependency Business success relies entirely on Haduvio development, regulatory approval, and commercialization across IPF, non-IPF ILD, and RCC.

Opioid Class Label Warning Risk Active ingredient carries opioid class warning; potential for restrictive marketing or distribution regulations if applied to Haduvio.

見通し

Key FDA Meeting Scheduled Planning End-of-Phase 2 meeting with FDA in Q4 2025; Phase 3 initiation for IPF expected in the first half of 2026.

Advance Multiple Clinical Programs Plan to initiate Phase 3 IPF trial and Phase 2b RCC trial in 2026, alongside ongoing TIDAL respiratory function study.

R&D Expenses Decreasing Nine month R&D expenses fell to $27.3M from $30.0M due to completion of several active Phase 2 clinical trials.

G&A Costs Increasing General and administrative expenses rose $2.6M for nine months, driven by personnel costs and SOX 404(b) compliance preparation.

同業比較

売上高 (TTM)

NVAX

$1.12B

+64.7%

ARDX

$407.32M

+22.1%

SNDX

$172.35M

+627.8%

粗利益率 (最新四半期)

SNDX

102.3%

-13.9pp

NBTX

100.0%

+0.0pp

IMTX

100.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
TERN	$3.83B	-41.3	-30.0%	0.3%
WVE	$2.55B	-12.1	-85.0%	2.8%
SYRE	$2.48B	-91.4	-29.4%	0.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月17日

EPS:-$0.10

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし